Stock 002932 WUHAN EASY DIAGNOSIS BIOMEDICINE CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

Equities

002932

CNE1000033Q7

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
19.59 CNY -1.61% Intraday chart for Wuhan Easy Diagnosis Biomedicine Co.,Ltd. -2.05% -14.71%
26/04 Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Proposes Final Cash Dividend for Year 2023 CI
01/04 Tranche Update on Wuhan Easy Diagnosis Biomedicine Co.,Ltd.'s Equity Buyback Plan announced on March 28, 2024. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022
Capitalization 1 2,938 2,411 4,350 7,761 8,945
Enterprise Value (EV) 1 2,516 2,041 3,622 5,915 4,640
P/E ratio 40.8 x 58.4 x 9.03 x 4.99 x 2.1 x
Yield 1.59% 0.28% 3.17% 6.08% 9.08%
Capitalization / Revenue 16.7 x 13.3 x 4.54 x 2.74 x 0.85 x
EV / Revenue 14.3 x 11.3 x 3.78 x 2.09 x 0.44 x
EV / EBITDA 36.6 x 42 x 6.45 x 3.47 x 0.9 x
EV / FCF -81.7 x -149 x 14 x 9.36 x 1.79 x
FCF Yield -1.22% -0.67% 7.17% 10.7% 55.8%
Price to Book 4.99 x 3.95 x 3.95 x 2.78 x 1.38 x
Nbr of stocks (in thousands) 2,06,956 2,06,956 2,14,478 2,32,840 2,32,728
Reference price 2 14.19 11.65 20.28 33.33 38.44
Announcement Date 24/04/19 29/04/20 14/05/21 26/04/22 20/04/23
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 165.1 176.4 181.2 959.1 2,830 10,530
EBITDA 1 77.82 68.66 48.63 561.8 1,704 5,180
EBIT 1 68.26 55.51 31.86 544.6 1,683 5,135
Operating Margin 41.34% 31.47% 17.59% 56.78% 59.47% 48.77%
Earnings before Tax (EBT) 1 75.43 70.83 46.55 556.7 1,695 5,076
Net income 1 65.49 61.42 41.53 468.9 1,413 4,208
Net margin 39.66% 34.82% 22.92% 48.89% 49.94% 39.97%
EPS 2 0.4215 0.3475 0.1995 2.246 6.675 18.31
Free Cash Flow 1 -18.47 -30.81 -13.74 259.6 631.6 2,590
FCF margin -11.19% -17.47% -7.58% 27.07% 22.32% 24.59%
FCF Conversion (EBITDA) - - - 46.21% 37.07% 49.99%
FCF Conversion (Net income) - - - 55.36% 44.7% 61.54%
Dividend per Share - 0.2252 0.0322 0.6435 2.027 3.490
Announcement Date 26/05/18 24/04/19 29/04/20 14/05/21 26/04/22 20/04/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 125 422 371 728 1,846 4,305
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -18.5 -30.8 -13.7 260 632 2,590
ROE (net income / shareholders' equity) 31.4% 15% 7.04% 55% 73% 91.1%
ROA (Net income/ Total Assets) 18.8% 7.94% 3.17% 33% 43.4% 50.9%
Assets 1 348.2 773.4 1,309 1,423 3,254 8,266
Book Value Per Share 2 1.550 2.840 2.950 5.140 12.00 27.90
Cash Flow per Share 2 0.8000 1.290 0.8200 3.120 5.110 11.00
Capex 1 45.5 47.5 31.9 28.3 104 313
Capex / Sales 27.57% 26.92% 17.63% 2.95% 3.66% 2.98%
Announcement Date 26/05/18 24/04/19 29/04/20 14/05/21 26/04/22 20/04/23
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
WUHAN EASY DIAGNOSIS BIOMEDICINE CO.,LTD. Stock Wuhan Easy Diagnosis Biomedicine Co.,Ltd.
-14.71% 629M
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.3B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
-5.02% 1.64B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 002932 Stock
  4. Financials Wuhan Easy Diagnosis Biomedicine Co.,Ltd.